Detalles de la búsqueda
1.
Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
J Infect Dis
; 225(10): 1701-1709, 2022 05 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34958382
2.
Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial.
Clin Infect Dis
; 75(1): e783-e791, 2022 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34551104
3.
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
PLoS Med
; 19(5): e1003953, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35617368
4.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet
; 396(10249): 479-488, 2020 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32702299
5.
Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study.
Expert Rev Vaccines
; 23(1): 498-509, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38695310
6.
Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study.
Emerg Microbes Infect
; 13(1): 2332660, 2024 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38678636
7.
Immunogenicity and safety of an ORF7-deficient skin-attenuated and neuro-attenuated live vaccine for varicella: a randomised, double-blind, controlled, phase 2a trial.
Lancet Infect Dis
; 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38614117
8.
Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study.
Vaccine
; 41(22): 3467-3471, 2023 05 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37127526
9.
Immunogenicity and Safety of One versus Two Doses of Quadrivalent Inactivated Influenza Vaccine (IIV4) in Vaccine-Unprimed Children and One Dose of IIV4 in Vaccine-Primed Children Aged 3-8 Years.
Vaccines (Basel)
; 11(10)2023 Oct 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37896989
10.
Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial.
Front Immunol
; 14: 1241153, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37799724
11.
A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age.
Hum Vaccin Immunother
; 19(2): 2235926, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37549923
12.
Addressing Unmet Needs in Vaccination for Older Adults in the Asia Pacific: Insights from the COVID-19 Pandemic.
Clin Interv Aging
; 18: 869-880, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37284594
13.
Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial.
Expert Rev Vaccines
; 22(1): 662-670, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432025
14.
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial.
Emerg Microbes Infect
; 12(1): 2155251, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36503413
15.
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial.
Lancet Infect Dis
; 23(11): 1313-1322, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37475116
16.
Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial.
Lancet Reg Health West Pac
; 34: 100731, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37283969
17.
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.
Lancet Respir Med
; 11(7): 613-623, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898400
18.
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.
Lancet Reg Health West Pac
; : 100829, 2023 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37360864
19.
Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial.
Sci Bull (Beijing)
; 68(20): 2448-2455, 2023 10 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37743201
20.
A novel influenza A (H1N1) vaccine in various age groups.
N Engl J Med
; 361(25): 2414-23, 2009 Dec 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-19846844